The biological activity of G-quadruplex DNA binding papaverine-derived ligand in breast cancer cells Blazej RubisMariusz KaczmarekMaria Rybczynska PRECLINICAL STUDIES 05 September 2008 Pages: 289 - 296
Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines Eleonore FröhlichInge FinkRichard Wahl PRECLINICAL STUDIES 20 September 2008 Pages: 297 - 303
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo Tashanna MyersShylet ChengedzaDoris M. Benbrook PRECLINICAL STUDIES Open access 18 September 2008 Pages: 304 - 318
p53-dependent antiproliferative and antitumor effect of novel alkyl series of diorganotin(IV) compounds Biplob KochTushar S. Basu BaulAnupam Chatterjee PRECLINICAL STUDIES 19 September 2008 Pages: 319 - 326
Synthesis and in vitro cytotoxic evaluation of novel diazaspiro bicyclo hydantoin derivatives in human leukemia cells: A SAR study C. S. Ananda KumarC. V. KavithaK. S. Rangappa PRECLINICAL STUDIES 07 October 2008 Pages: 327 - 337
Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes: search for potent and safe HDAC inhibitors Joanna FraczekSarah DeleuVera Rogiers PRECLINICAL STUDIES 30 September 2008 Pages: 338 - 346
Chemopreventive potential of Epoxy clerodane diterpene from Tinospora cordifolia against diethylnitrosamine-induced hepatocellular carcinoma Muniyappan DhanasekaranArul-Albert BaskarVeeramuthu Duraipandiyan PRECLINICAL STUDIES 14 October 2008 Pages: 347 - 355
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors Axel-R. HanauskeHerlinde DumezAhmad Awada PHASE I STUDIES 28 October 2008 Pages: 356 - 365
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer William P. TewDelia RadovichDavid H. Ilson PHASE I STUDIES 28 October 2008 Pages: 366 - 373
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer C. D. BlankeT. M. BeerC. Lopez PHASE II STUDIES 09 October 2008 Pages: 374 - 378
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure R. DreicerW. M. StadlerA. Pantuck PHASE II STUDIES 18 October 2008 Pages: 379 - 386
Major response to sunitinib (Sutene®) in metastatic malignant phyllodes tumor of breast In Hae ParkYoungmee KwonJungsil Ro SHORT REPORT 11 November 2008 Pages: 387 - 388
Blackberry-induced hand-foot skin reaction to sunitinib Susan L. BooneGayle JamesonMario E. Lacouture SHORT REPORT 08 November 2008 Pages: 389 - 390
Blackberry-induced hand-foot skin reaction to sunitinib Susan L. BooneGayle JamesonMario E. Lacouture Erratum 18 February 2009 Pages: 391 - 391